|ATC code||N01AH05 (WHO)|
|Protein binding||> 95%|
|Chemical and physical data|
|Molar mass||352.47 g/mol|
|3D model (Jmol)||Interactive image|
|Melting point||83 °C (181 °F)|
|(what is this?)|
Anileridine (trade name: Leritine) is a synthetic analgesic drug and is a member of the piperidine class of analgesic agents developed by Merck & Co. in the 1950s. It differs from pethidine (meperidine) in that the N-methyl group of meperidine is replaced by an N-aminophenethyl group, which increases its analgesic activity.
Anileridine is no longer manufactured in the US or Canada. Anileridine is in Schedule II of the Controlled Substances Act 1970 of the United States as ACSCN 9020 with a zero aggregate manufacturing quota as of 2014. The free base conversion ratio for salts includes 0.83 for the dihydrochloride and 0.73 for the phosphate It is also under international control per UN treaties.
Anileridine usually takes effect within 15 minutes of either oral or intravenous administration, and lasts 2–3 hours. It is mostly metabolized by the liver.
- U.S. Patent 2,897,204
- "Discontinued Prescription Drug Products". Canadian Pharmacists' Association. Retrieved 28 July 2008.
- "Pharmaceutical Information - LERITINE". RxMed. Retrieved 16 June 2010.
- "Anileridine Consumer Information". MedicineNet. Retrieved 28 July 2008.